by Raynovich Rod | Sep 25, 2015 | Biopharmaceuticals
After the close 9/25…The bio-bubble has burst. XBI down 6.85%, IBB down 4.91%. Can healthcare sector recover? —– Bull Market Intact But Sentiment Has Turned Negative The severe 20%++ correction in the biotech sector is getting a lot of bearish...
by Raynovich Rod | Sep 21, 2015 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Update-1… 9/22/15 …Biotech Stocks Trade Down Another Day Biotech stocks were weak tracking NASDAQ which was down 1.5%. The IBB was down 1.49% to $335.40 flat over one month and up 10.57% YTD. The August low was $325 and the IBB is 16% off July 20 highs....
by Raynovich Rod | Jul 16, 2015 | Biopharmaceuticals
Biotech Stocks More Subdued- as of Mid-Day 7/20 Trading Biotechnology stocks are taking a rest today after a torrid five days that saw the XBI up 7.31%, FBT up 6.19% and the IBB up 6.65%. Moreover on Friday 7/17 the trading in six or more biotech small caps made the...
by Raynovich Rod | Jun 24, 2015 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Updated 6/25 Precision Medicine -Novel Prevention and Treatment Strategies Lead The Way A New Initiative on Precision Medicine — NEJM Over 15,000 attended BIO 2015 in Philadelphia including 1100 companies and more than 30 nations. The Exhibits and Partnering meetings...
by Raynovich Rod | Jun 9, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Updated 6/10 Biotech ETFs lag overall in 1.4% rally. Materials, financials and technology lead. Large cap biotechs doing well. Rayno portfolio winners today: ALXN, BIIB, GILD, RHHBY etc Rapid Fire Re-Balancing of ETFs into More Speculative Names Is the Tail Wagging...
by Raynovich Rod | Jun 7, 2015 | 2024 Rayno Biopharmaceuticals Portfolio
ASCO Week in Review- Rayno Biopharmaceutical Stocks The market action over the past week focused on speculative stocks rather than the overall biopharmaceutical sector. Major ETFs over five days were mixed with the smaller cap XBI up over 1%, the IBB flat and the FBT...
by Raynovich Rod | Jun 2, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 BLUE Drops 1.96% and 1.77% After Hours 6/3 In the bubbly CAR-T world bluebird bio (BLUE) and Celgene announced a deal for for development of product candidates for B-cell maturation antigen (BMCA) utilizing bluebird bios’s gene therapy technology to...
by Raynovich Rod | May 27, 2015 | Biopharmaceuticals
Update-1 Mixed Market but CAR-T stocks soar Biotechs could not break through the top today and were down about 0.5%. The XBI and XLV did a little better almost flat. Red and green were just about mixed among many stocks. Biomarin (BMRN) a “rare disease”...
by Raynovich Rod | May 20, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 uniQure up on deal with BMY (CURE) Cardiovascular Deal with Bristol Myers (BMY) The closing of the uniQure deal with Bristol Myers triggered a $50M payment. Three collaboration targets in cardiovascular and future areas. The stock is up 81% YTD but off its...
by Raynovich Rod | May 8, 2015 | 2024 Rayno Biopharmaceuticals Portfolio
Jobs Report Drive Stocks Higher-DOW Up 1.5% Stocks moved higher on the “goldilocks” job report which showed a gain of 223k added in April. The jobs number was too high to raise concerns about an increase in rates but not too bullish because overall...